GlucoSentient
US-based Glucosentient, Inc, founded in 2011, specializes in manufacturing diagnostic substances.
Founded
2011US-based Glucosentient, Inc, founded in 2011, specializes in manufacturing diagnostic substances.
Founded in 2011, GlucoSentient, Inc. is a US-based company located in Champaign, specializing in the manufacturing of in vitro and in vivo diagnostic substances. The company's core mission is to revolutionize the Blood Glucose Meter (BGM) by transforming it into a versatile diagnostic platform. GlucoSentient aims to leverage the widespread use and proven reliability of BGMs to create a powerful tool capable of measuring various health indicators, thereby enhancing diagnostic capabilities for millions of diabetics and potentially other patient groups globally.
GlucoSentient has garnered attention for its innovative approach to medical diagnostics, though specific notable affiliated people and investors are not publicly detailed. The company’s key achievement lies in its development of an enhanced BGM technology that promises to expand the utility of this common medical device beyond glucose measurement. This innovation positions GlucoSentient as a significant player in the diagnostic technology market, with the potential to impact healthcare practices and patient outcomes positively.
Companies similar to GlucoSentient include GlucoVista, Glumetrics, Glucon and Glysens.
GlucoSentient was founded in 2011.
GlucoSentient's headquarters is located in Champaign, IL, US.
GlucoSentient's most recent funding round was for $900k (USD) in September 2013.
As of Sep 16, 2013, GlucoSentient has disclosed funding of $1.1M (USD). Undisclosed round amounts are excluded.
GlucoSentient has 7 employees as of Feb 5, 2024.
